Navigation Links
An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market
Date:8/31/2010

BURLINGTON, Mass., Aug. 31 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.

The Pharmacor 2010 findings from the topic entitled Chronic Obstructive Pulmonary Disease reveal that the COPD drug market, which totaled nearly $8.4 billion in 2009, will reach more than $13 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The findings also reveal that the drug-treated COPD population will increase by nearly 6 million patients over the next decade. Although two maintenance therapies currently dominate the COPD market—GlaxoSmithKline's Advair/Seretide/Adoair and Boehringer Ingelheim/Pfizer's Spiriva—the near-term market will become fractured owing to the launch of new agents and generic erosion of key brands.

The Pharmacor 2010 findings also reveal that the makers of lower-priced branded generics will capitalize on the loss of market exclusivity of Advair/Seretide/Adoair and Spiriva in the United States and Europe, and generic versions of these drugs will become available in Europe by 2019.

"Challenging regulatory environments, uncertain pricing and reimbursement restrictions and the loss of patent protection and/or market exclusivity for many top-selling COPD products will constrain the COPD market," said Decision Resources Analyst Benjamin Guikema, Ph.D. "However, manufacturers of generic products will face great barriers to entering the COPD market, given the lack of clear regulatory pathways and the difficulty of creating a device that is acceptable to regulators, physicians and patients."

The findings also reveal that the launch of fixed-dose combination inhalers containing a lon
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
2. China BCT Acquires 11 Stores, Expanding Retail Pharmacy Network
3. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
4. Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients
5. Elsevier is Expanding eClinical Solutions in Europe
6. Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products
7. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
8. Expert Healthcare Panel Recommends Select Nutritional Support for Baby Boomers for Healthy Aging to Maintain Active Lifestyles
9. +PLUSPAK (polymer bottle) Packaging Receives GEs Distinguished ecomagination(SM) Approval
10. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
11. MedInformatix RIS Improves 60-Year-Old Radiology Business Cash Flow and Accounts Receivable, Speeding Accounts Receivable on Full Breadth of Imaging Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 IRIDEX Corporation (NASDAQ: IRIX ) ... 2015 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, August 6, 2015 to ... developments. Interested parties may access the live ...
(Date:7/30/2015)... PARK, N.J. , July 30, 2015  Unichem ... voluntarily recalling one lot of Hydrochlorothiazide tablets 25 mg ... been initiated as a precautionary measure due to the ... of the product. The risk associated ... Hydrochlorothiazide tablet is the increased probability of experiencing Clopidogrel,s ...
(Date:7/30/2015)... China , July 30, 2015 Tianyin ... a pharmaceutical company that specializes in the patented biopharmaceutical, ... pharmaceutical ingredients (API), provided updates regarding the notice it ... LLC (the "Exchange") indicating that the Company was below ... forth in Sections 134 and 1101 of the NYSE ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... SEATTLE, Oct. 15 Omeros Corporation (Nasdaq: ... and commercializing products focused on inflammation and disorders of ... Demopulos, M.D., chairman and chief executive officer, will present ... on October 22, 2010 at 1:30 p.m. Eastern time ...
... Tolerated in Multiple Sclerosis Patients -- PARIS, October 15, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 2Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 3Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 4Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 5Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 6Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 7Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 8Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 9Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 10Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 11Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients 12
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, ... Phil reached Connecticut and was greeted by friends and family. He visited CCAR and ...
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently ... know in predictive health analytics , Jvion continues to disrupt the predictive ... predictive software that targets patient and population level illness to drive prevention and ...
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... new study by the Canadian Institute for Health Information has found ... //that they could prove to be fatal. The study also found ... as well. ,'Now is the first time we know ... why might this be?' said Jennifer Zelmer, vice president of research ...
... of Agriculture Director of Veterinary and Livestock Services, was ... the International Committee of the World Organisation for Animal ... elected the President of OIE. This post is held ... during the 74th Annual General Session of (OIE) in ...
... waiting lists for patients in Britain, they are forced into taking treatment ... citing an arthritis case of an Ulster man, who had to pay ... done free if by NHS. But the waiting list was too long ... - Humira and Enbrel - for rheumatoid arthritis. The bad part is ...
... AIDS Society is grossly disappointed with the UN General Assembly ... all the earmarked prevention programs needed to battle the pandemic. ... International AIDS Society said 'The lack of clear targets I ... workers we need in order to deliver prevention and treatment ...
... company could block the spread of HIV, say scientists after ... ,Human Immunodeficiency Virus (HIV) steadily weakens the body's immune ... as pneumonia, diarrhea, tumours and other illnesses. ... of the first signs of the disease. Most of all ...
... has cleared the class X examination - a feat no ... ,The Belagadia village, some 150 km from the state ... It does not have a school. ,Jharana Sahu ... at a high school in nearby Kalupur village. "Jharana successfully ...
Cached Medicine News:Health News:New Revolutionary Drug Could Stop the Spread of HIV 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: